A Proof of Concept Study to Investigate the Effect of a New Treatment in Patient With Chronic Pain

A Proof of Concept Study to Investigate the Effect of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain or Osteoarthritic Pain of Knee or Hip

The purpose of this clinical trial conducted in patients suffering from chronic pain is to study the relationship between individual patients' profile and their analgesic response

Study Overview

• Status: Completed
• Conditions: Osteoarthritis; Peripheral Neuropathies
• Intervention / Treatment: Behavioral: Heat Pain Stimuli A; Behavioral: Positive Video; Drug: Administration of T4P1001 capsules; Behavioral: Heat Pain Stimuli B; Behavioral: Neutral Video; Drug: Administration of Placebo capsules

• Study Type: Interventional
• Enrollment (Actual): 114
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Liège, Belgium, 4000
    • ATC SA
• France
  • Clermont-Ferrand, France, 63003
    • CIC Clermont-Ferrand, CHU Clermont-Ferrand
  • Gières, France, 38610
    • Eurofins Optimed
  • Nantes, France, 44046
    • Clinique Breteche
  • Paris, France, 75005
    • Institut Curie
  • Saint-Etienne, France, 42055
    • Centre d'Evaluation et Traitement de la Douleur, CHU Saint-Etienne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Are men or women of at least 18 years of age
• Diagnosed with Peripheral Neuropathic Pain (PNP) or knee or hip pain attributed to Osteoarthritis (OA) since at least 6 months
• Affiliated with national welfare
• Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
• Have given written informed consent approved by the relevant Ethics Committee (EC) governing the study sites
• Patients will be required to report pain with a score between 4 and 8 inclusive on the mean Average Pain Score (APS) during the baseline period preceding randomization and to have completed at least 10 days of pain assessments in their diary between Visit 1 and Visit 2. If more than 10 days were completed, the mean APS will be calculated on the last 10 ones.

Inclusion Disease Criteria:

• Diagnosis criterium for PNP: Patient with chronic PNP supported by a distinct neuroanatomical plausible distribution with sensory signs and symptoms, and consecutive to one of the following causes: a traumatic event, a surgical procedure (excluding limb amputation), radiculopathy, post- herpetic or post- zoster neuralgia, diabetic polyneuropathy or post chemotherapy. Diagnosis will have to be confirmed by the DN4 questionnaire at the screening visit (pain is considered as neuropathic if DN4 score ≥ 4)

• Diagnosis criterium for OA: Patient with a unilateral or bilateral OA of the knee or hip diagnosed according to the American College of Rheumatology (ACR) criteria based on clinical and radiographic evidence (Altman et al. 1986). The clinical diagnosis of OA will be confirmed by the ACR clinical and radiographic criteria for classification of idiopathic OA of the knee or hip based upon the following criteria:

  1. Knee or hip pain as an average at least half of the time for the last 3 months before screening visit
  2. At least 1 of the following 3 conditions: Age > 50 or morning stiffness < 30 minutes or crepitus
  3. Kellgren and Lawrence grade > 1 as assessed if possible by an X-ray of the referred joint to confirm the diagnosis. If considered medically required by the Investigator based on patient needs and as part of regular patient management, a new anterior-posterior view X- ray should be obtained and reviewed by Investigator or his delegates to verify that the patient meets the disease diagnostic criteria

Exclusion Criteria:

• Patient changed his/her " regular analgesic therapy " for PNP or OA in the last 4 weeks prior to Visit 1 or during the study.
• Patient's regular analgesic treatment for PNP or OA consists of more than 2 different treatments, with neurostimulation being considered as an analgesic treatment for PNP.
• Patient reported unvariable APS and WPS scores between Visit 1 and Visit 2 (systematically the same APS score and the same WPS score reported).
• Use or plan to use non-topical corticosteroids during the study.
• Have initiated (or plan to initiate) a program (or modify an existing program in frequency and/or intensity) of physiotherapy or behavioral therapy such as pain self-management, hypnosis, sophrology, meditation program within 2 weeks prior to Visit 1 or during the study.
• Pregnant, breastfeeding, or willing to be pregnant within 3 months.
• Patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the study.
• Uncontrolled epilepsy.
• Any current primary psychiatric condition, including depression or personality disorders (such as Axe II of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); personality disorders and mental retardation).
• Alcohol dependence or regular use of known drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and phencyclidine).
• Any other relevant medical disorder/acute disease state judged by the Investigator as likely to interfere with the trial or represent a risk for the patient.
• Any close relationship with the Investigators or the Sponsor (i.e. belonging to immediate family or subordination link).
• Patient under legal protection, according to the national law.
• Are persons who have previously received T4P1001, have completed or withdrawn from this study or any other study investigating T4P1001.
• Patient currently enrolled in a clinical trial involving use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or in an exclusion period according to the national law.

Exclusion Disease Criteria for PNP patients:

• Neuropathic pain due to trigeminal neuralgia, central pain or phantom limb pain.
• Have initiated, are planning to initiate an electrical stimulation (or neurostimulation) therapy or modify an existing neurostimulation within 4 weeks prior to Visit 1 or during study period.

Exclusion disease criteria for OA patients:

• Non-ambulatory due to OA.
• Use of lower extremity assistive devices other than a cane such as crutches or walker or a knee brace or a "shoe lift" in relation to OA.
• Have used in relation to OA systemic corticosteroids 4 weeks prior to Visit 1; Intra-muscular corticosteroid injections or Intra-articular injection of steroids into the referred knee/hip within 3 months before Visit 1, Intra-articular injection of corticosteroids into any other sites than the referred knee/hip within 4 weeks prior to Visit 1(corticosteroids in topical use are allowed).
• Have used viscosupplementation or intra articular injection of hyaluronic acid in the referred joint within 3 months prior to Visit 1.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: Placebo	Behavioral: Heat Pain Stimuli B; Behavioral: Neutral Video; Drug: Administration of Placebo capsules; This treatment is given as add-on therapy to patient's regular analgesic treatment
Active Comparator: T4P1001	Behavioral: Heat Pain Stimuli A; Behavioral: Positive Video; Drug: Administration of T4P1001 capsules; This treatment is given as add-on therapy to patient's regular analgesic treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment	11-point Numeric Rating Scale (NRS); the 11 NRS scale ranges from 0 (No pain) to 10 (pain as bad as you can imagine); the baseline APS (weekly mean of the daily average pain score) was computed on the 7 last days before Visit 2 with available APS values; similarly, the end-of-treatment APS (or APS Week 4) was computed on the 7 last days before Visit 4 with available APS values.	Time zero equals baseline (Day-28 to Day-14) up to Day 36

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI)	BPI is a self-reported scale that measures the severity of pain and the interference of pain on function (Charles S. Cleeland © 2009). In the short form of BPI, there are 4 questions assessing worst pain, least pain, actual pain and average pain in the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as bad as you can imagine). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. The interference scores range from 0 (does not interfere) to 10 (completely interferes).	Time zero equals baseline (Day-28 to Day-14) up to Day 29
Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC)	IGAC and PGAC are subjective evaluations using a NRS with 0 meaning "best condition" and 10 "worst condition"	Time zero equals baseline (Day-28 to Day-14) up to Day 29
Patient's Change From Baseline of Heat Pain Threshold From Baseline to End of Treatment	celcius degree, arithmetic average of 6 tests.	Time zero equals baseline (Day 1) up to Day 29
For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment	The WOMAC (Bellamy et al., 1988) is a patient-rated instrument that measures OA symptoms. The questionnaire contains 5 pain questions, 2 stiffness questions, and 17 physical function questions (24 questions total). Each question utilizes a 5-points Numeric Rating Scale (NRS) between 0-4; from 0=none to 4=extreme. Range of possible subscale scores: pain=0-20, stiffness=0-8 and physical function=0-68; higher scores for each subscale indicate worse outcomes. The WOMAC was completed at each Visit except for Visit 5 by OA patients only.	Time zero equals baseline (Day-28 to Day-14) up to Day 29

Collaborators and Investigators

• Sponsor: Tools4Patient
• Collaborators: International Drug Development Institute
• Investigators: Study Director: Alvaro Pereira, Tools4Patient

Study record dates

Study Major Dates

• Study Start: June 1, 2015
• Primary Completion (Actual): October 1, 2016
• Study Completion (Actual): October 1, 2016

Study Registration Dates

• First Submitted: May 28, 2015
• First Submitted That Met QC Criteria: May 29, 2015
• First Posted (Estimate): June 1, 2015

Study Record Updates

• Last Update Posted (Actual): August 28, 2019
• Last Update Submitted That Met QC Criteria: August 16, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Keywords: Pain
• Additional Relevant MeSH Terms: Nervous System Diseases; Neuromuscular Diseases; Peripheral Nervous System Diseases
• Other Study ID Numbers: T1001-02